Osteopontin binds ICOSL promoting tumor metastasis

Davide Raineri,Chiara Dianzani,Giuseppe Cappellano,Federica Maione,Gianluca Baldanzi,Ilaria Iacobucci,Nausicaa Clemente,Giulia Baldone,Elena Boggio,Casimiro L. Gigliotti,Renzo Boldorini,Josè M. Rojo,Maria Monti,Leila Birolo,Umberto Dianzani,Annalisa Chiocchetti

DOI: https://doi.org/10.1038/s42003-020-01333-1

IF: 6.548

2020-10-26

Communications Biology

Abstract:Abstract ICOSL/ICOS are costimulatory molecules pertaining to immune checkpoints; their binding transduces signals having anti-tumor activity. Osteopontin (OPN) is here identified as a ligand for ICOSL. OPN binds a different domain from that used by ICOS, and the binding induces a conformational change in OPN, exposing domains that are relevant for its functions. Here we show that in vitro, ICOSL triggering by OPN induces cell migration, while inhibiting anchorage-independent cell growth. The mouse 4T1 breast cancer model confirms these data. In vivo, OPN-triggering of ICOSL increases angiogenesis and tumor metastatization. The findings shed new light on ICOSL function and indicate that another partner beside ICOS may be involved; they also provide a rationale for developing alternative therapeutic approaches targeting this molecular trio.

biology